TransCode Therapeutics, Inc.

NasdaqCM:RNAZ Stock Report

Market Cap: US$6.8m

TransCode Therapeutics Management

Management criteria checks 3/4

TransCode Therapeutics' CEO is Philippe Calais, appointed in Oct 2025, has a tenure of less than a year. directly owns 0% of the company’s shares, worth $7.49. The average tenure of the management team and the board of directors is 7.4 years and 4.9 years respectively.

Key information

Philippe Calais

Chief executive officer

US$212.5k

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownership0.0001%
Management average tenure7.4yrs
Board average tenure4.9yrs

Recent management updates

Recent updates

TransCode Therapeutics reports Q2 results

Aug 15

TransCode files U.S. patent application for radiotherapy based cancer treatment

Jul 11

We're Hopeful That TransCode Therapeutics (NASDAQ:RNAZ) Will Use Its Cash Wisely

Apr 01
We're Hopeful That TransCode Therapeutics (NASDAQ:RNAZ) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About TransCode Therapeutics' (NASDAQ:RNAZ) Cash Burn Situation

Dec 15
Here's Why We're Not Too Worried About TransCode Therapeutics' (NASDAQ:RNAZ) Cash Burn Situation

CEO

Philippe Calais (66 yo)

less than a year
Tenure
US$212,535
Compensation

Dr. Philippe P. Calais, Pharm. D. Ph.D. served as President, Chief Executive Officer and Director of MatriSys Bioscience, Inc. since January 13, 2024. Dr. Calais has been Executive Chairman of the Board of...

Leadership Team

NamePositionTenureCompensationOwnership
Philippe Calais
CEO & Executive Chairman of the Boardless than a yearUS$212.54k0.00011%
$ 7.5
Thomas Fitzgerald
CFO, President7.4yrsUS$956.97k0.00022%
$ 15.0
Zdravka Medarova
Co-Founder & Chief Scientific Officer9.9yrsno datano data
Anna Moore
Co-Founder9.9yrsno datano data
Susan Duggan
Senior Vice President of Operationsno datano datano data
Daniel Vlock
Chief Medical Officer1.8yrsno datano data
7.4yrs
Average Tenure
66yo
Average Age

Experienced Management: RNAZ's management team is seasoned and experienced (7.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Philippe Calais
CEO & Executive Chairman of the Board7.2yrsUS$212.54k0.00011%
$ 7.5
Thomas Fitzgerald
CFO, President7.4yrsUS$956.97k0.00022%
$ 15.0
Anna Moore
Co-Founder9.9yrsno datano data
Elizabeth Czerepak
Independent Directorless than a yearno datano data
Phillip Zamore
Member of Scientific Advisory Boardless than a yearno datano data
Magda Marquet
Independent Director4.9yrsUS$62.54k0%
$ 0
Keith Flaherty
Member of Advisory Boardno datano datano data
Lubomir Nechev
Member of Advisory Board4.8yrsno datano data
Frank Slack
Member of Advisory Board3.3yrsno datano data
Dejan Juric
Member of Advisory Board4.3yrsno datano data
Erik Manting
Independent Director5yrsUS$60.54k0%
$ 0
4.9yrs
Average Tenure
66yo
Average Age

Experienced Board: RNAZ's board of directors are considered experienced (4.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/26 02:18
End of Day Share Price 2025/12/26 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

TransCode Therapeutics, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Emily BodnarH.C. Wainwright & Co.